IL12B (rs3213094) gene variant in people with psoriasis
Official title: Evaluation of IL 12B Genetic Polymorphism (rs3213094) in Patient With Psoriasis and Psoriatic Arthritis in Response to Humira
Run by South Valley University · NCT07128472 · Data updated 2026-11-12
This test looks at whether a specific IL12B gene change (rs3213094) is linked to how people with moderate-to-severe psoriasis respond to Humira.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | South Valley University Academic / other |
| Drugs / interventions | adalimumab |
| Locations | 1 site (Qina) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | January 20, 2026 |
| Study ends | February 1, 2026 |
| Registry record updated | August 19, 2025 |
| Trial ID | NCT07128472 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with clinically diagnosed psoriasis for at least six months, severe disease (PASI >10 and >10% BSA) and who are receiving Humira are the intended participants.
✕Probably not a fit
People with other autoimmune or inflammatory conditions, active infections, pregnancy or lactation, known immune genetic disorders, contraindications to Humira, or those not on Humira are excluded and unlikely to benefit from the findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study enrolls people with clinically diagnosed moderate-to-severe psoriasis who are being treated with Humira and genotypes them for the IL12B rs3213094 polymorphism. Participants receive standard Humira therapy while investigators collect clinical outcome measures, including PASI scores and assessments for psoriatic arthritis. The study aims to correlate the genetic variant with treatment response and disease features. Data will be analyzed to see if the IL12B variant predicts better or worse outcomes on Humira.
Why it matters
Potential benefit: If successful, this could help personalize psoriasis treatment by identifying patients more likely to respond to Humira based on their IL12B genotype.
How similar studies have gone: Genetic studies have linked IL12B variants to psoriasis risk, but using rs3213094 specifically to predict Humira response is relatively limited and not yet well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis. Exclusion Criteria: * Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus). * Pregnancy and lactation. * Patients currently undergoing any treatment other than Humira. * Patients with known genetic disorders affect immune system function. * Patients were undergoing any treatment other than Humira in the last 6 months. * Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV). * Patients with contraindication to Humira. * Renal \&Vascular diseases
Where it's running
-
Qina University hospital, South Valley University Hospital
Qina, Egypt Recruiting
Study contacts
- Principal investigator: Mohamed Hosny Hassan, Professor — Medical Biochemistry Department,Qena Faculty of Medicine,south valley university
- Study coordinator: Alaa Ahmed Saad Ali Aweida, MSc
- Email: alaaahmed201666@gmail.com
- Phone: +201119814470
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HB0017 Injection safety and PK in low-weight adults at different injection sites
This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.
-
MK-8644: first-in-human test in healthy people and people with psoriasis
This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.
-
Is XJH05 Ointment Effective for Plaque Psoriasis?
This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.
-
Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care
This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.
-
TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis
This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.
-
SHR-1139 injectable treatment for adults with plaque psoriasis
This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.